CN103251850A - Traditional Chinese medicine mixture for treating psoriasis - Google Patents
Traditional Chinese medicine mixture for treating psoriasis Download PDFInfo
- Publication number
- CN103251850A CN103251850A CN2013101973371A CN201310197337A CN103251850A CN 103251850 A CN103251850 A CN 103251850A CN 2013101973371 A CN2013101973371 A CN 2013101973371A CN 201310197337 A CN201310197337 A CN 201310197337A CN 103251850 A CN103251850 A CN 103251850A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- fructus
- chinese medicine
- medicine mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Abstract
The invention discloses a traditional Chinese medicine mixture for treating psoriasis. The traditional Chinese medicine mixture is prepared from the following medicaments in parts by weight: rhizoma alismatis, smoked plum, radix clematidis, herba schizonepetae, honeysuckle, rhizoma coptidis, poria cocos, spreading hedyotis herb, donkey-hide gelatin, plaster stone, motherwort fruit, belvedere fruit, buckwheat, snake slough, radix rehmanniae, dittany bark, coix seed, winged euonymus twig, lightyellow sophora root, licorice, Chinese wax gourd peel, caulis spatholobi, papaya and polygonum multiflorum thunb. The traditional Chinese medicine mixture has effects of eliminating diseases of patients and promoting physical and mental health of the patients, and has outstanding substantive characteristics and significant improvements of low treatment cost, convenience for the patients to take and rapid curative effect without side effects to treat the psoriasis.
Description
Technical field
The invention belongs to the Chinese medicine technical field, relate to a kind of Chinese medicine mixture, be specifically related to a kind of technical field that is used for the treatment of psoriatic Chinese medicine mixture.
Background technology
Psoriasis claims psoriasis again, is a kind of common chronic inflammatory disease dermatoses, has the characteristics of intractable and recurrent.Psoriasis is sent out well in exposed position, as positions such as head, extremity, shirtfront, back.Though threat to life through obstinate, is not delayed recurrence year by year and is increased the weight of.
Psoriasis is neither any incurable disease more has absolutely nothing to do with each other with " second cancer ", and Chinese scholars has been explored a whole set of effective method for treatment through long-term clinical practice.In recent years, more there are many new medicines and therapy to come out, make psoriatic treatment that significant progress arranged.Therefore, seek a kind of illness new, that can eliminate the patient, have take medicine conveniently, curative effect is fast, the psoriatic Chinese medicine mixture that is used for the treatment of that have no side effect is still the problem that those skilled in the art need to be resolved hurrily.
Summary of the invention
Goal of the invention: the present invention provides a kind of psoriatic Chinese medicine mixture that is used for the treatment of for solving the problems of the technologies described above.
Technical scheme:For solving the problems of the technologies described above, the present invention adopts following technical scheme: a kind ofly be used for the treatment of psoriatic Chinese medicine mixture, it is characterized in that being made up of following medicaments in part by weight: Rhizoma Alismatis 10-40 part, Fructus Mume 10-40 part, Radix Clematidis 5-20 part, Herba Schizonepetae 10-40 part, Flos Lonicerae 15-45 part, Rhizoma Coptidis 15-45 part, Poria 10-40 part, Herba Hedyotidis Diffusae 15-45 part, Colla Corii Asini 15-50 part, Gypsum Fibrosum 10-30 part, Fructus Leonuri 10-40 part, Fructus Kochiae 10-40 part, Semen Fagopyri Esculenti 10-40 part, Periostracum Serpentis 10-40 part, Radix Rehmanniae 10-40 part, Cortex Dictamni 20-60 part, Semen Coicis 20-60 part, Ramulus Euonymi 5-30 part, Radix Sophorae Flavescentis 10-40 part, Radix Glycyrrhizae 5-20 part, Exocarpium Benincasae 15-50 part, Caulis Spatholobi 10-40 part, Fructus Chaenomelis 5-15 part, Radix Polygoni Multiflori 15-45 part.
For further solving the problems of the technologies described above, the preferred version of said medicine weight portion is: Rhizoma Alismatis 20-30 part, Fructus Mume 20-30 part, Radix Clematidis 10-15 part, Herba Schizonepetae 20-30 part, Flos Lonicerae 25-35 part, Rhizoma Coptidis 25-35 part, Poria 20-30 part, Herba Hedyotidis Diffusae 25-35 part, Colla Corii Asini 20-45 part, Gypsum Fibrosum 15-25 part, Fructus Leonuri 20-30 part, Fructus Kochiae 20-30 part, Semen Fagopyri Esculenti 20-30 part, Periostracum Serpentis 20-30 part, Radix Rehmanniae 20-30 part, Cortex Dictamni 30-50 part, Semen Coicis 30-50 part, Ramulus Euonymi 10-20 part, Radix Sophorae Flavescentis 20-30 part, Radix Glycyrrhizae 10-15 part, Exocarpium Benincasae 20-40 part, Caulis Spatholobi 15-30 part, Fructus Chaenomelis 10-15 part, Radix Polygoni Multiflori 15-35 part.
For further solving the problems of the technologies described above, the preferred plan of said medicine weight portion is: 30 parts of Rhizoma Alismatis, 25 parts of Fructus Mumes, 15 parts of Radix Clematidis, 25 parts of Herba Schizonepetae, 30 parts of Flos Loniceraes, 30 parts of Rhizoma Coptidis, 25 parts in Poria, 30 parts of Herba Hedyotidis Diffusaes, 40 parts in Colla Corii Asini, 20 parts of Gypsum Fibrosum, 25 parts of Fructus Leonuris, 25 parts of the Fructus Kochiae, 25 parts in Semen Fagopyri Esculenti, 25 parts of Periostracum Serpentiss, 25 parts in the Radix Rehmanniae, 40 parts of Cortex Dictamnis, 40 parts of Semen Coicis, 15 parts of Ramulus Euonymis, 25 parts of Radix Sophorae Flavescentiss, 12 parts in Radix Glycyrrhizae, 30 parts of Exocarpium Benincasaes, 20 parts of Caulis Spatholobis, 10 parts of Fructus Chaenomeliss, 20 parts of Radix Polygoni Multifloris.
Chinese medicine mixture described above according to the conventional technology of preparing of Chinese medicine make pill, sublimed preparation, powder, tablet, unguentum,
Decoction and the different oral medicine dosage form of capsule dress powder.
Chinese medicine mixture described above also contains drug excipient.
Chinese medicine mixture described above is used for the application as treatment psoriasis disease.
The principles of formulating prescriptions of Chinese medicine mixture of the present invention are: regulating the blood flow circulation, painful antipruritic, the cooling blood and dissolving purpura of clearing away heart-fire, expelling wind and removing dampness, kidney tonifying detoxifcation, town, enhancement telangiectasis improve immune function of human body, thereby reach the psoriatic purpose for the treatment of.The present invention has proper, the reasonable recipe of compatibility of drugs, according to the Chinese medicine of the different configurable various dose of the course of disease; Prescription is novel, and the drug effect complementation is with low cost, psoriasis is had excellent curative, and have no side effect.
Beneficial effect:The clinical use result of Chinese medicine mixture of the present invention shows to have following advantage:
1, the Chinese medicine mixture each component selected for use of the present invention meets the regulation of the Drug Administration Law of People's Republic of China, utilizes comprehensive function treatment and the prevention psoriasis disease of the Chinese medicine of respectively distinguishing the flavor of, and is nontoxic to human body.Acute toxicity test and accumulation toxicity test through white mice and rat show that underproof animal does not see any toxic reaction, compare zero difference through anatomic observation hemogram, liver function, each organs and tissues morphology finding and matched group, prove that its safety of medicine is reliable.
2, Chinese medicine mixture preparation of the present invention need not decoct, not have bitterness sense, rich in proteins, glucose, glucuronic acid, volatile oil, pectin, fructose, organic acid, lecithin, vitamin, aminoacid in the medicine, also contain various trace elements such as Saponin, plant sterol, calcium, be conducive to absorption of human body, health invigorating, and taking convenience.
3, Chinese medicine mixture preparation of the present invention not only can effectively be treated the psoriasis disease, and it is also very obvious to the preventive effect of psoriasis disease, particularly by working in coordination with mutually between the medicine, strengthen medicine and treat characteristic separately, by dredge the meridian passage and adjusting immunologic function, improve healthy energy and physical and mental health and the life quality of patient body inherence, reached the healing rehabilitation efficacy preferably.
Further specify Chinese medicine mixture of the present invention to treating psoriatic effect below by clinical practice.
One, clinical diagnosis standard:
The inspection of skin living cells shows unusually:
1. the prominent neat prolongation of skin and bottom thicken.
2. dermal papilla prolongs and edema.
3. granular layer disappears.
4. parakeratosis.
5.MUNRO microabscess.
Two. case selection
All can be used as case for the patient who meets above-mentioned disease and observe, especially weak and sickly, middle-aged and elderly people, women, child are observed as first-selected case especially; The method of observing is then carried out complete observation by the method for hoping, asking, hearing, cutting to the patient; And for of all ages, the sex of the heavier patient of the state of an illness, without exception as the direct study subject of observing treatment.
Three. administrated method
According to psoriatic's severe extent, the length of sick time, adopt interior with oral of the present invention
The Chinese medicine mixture is treated psoriasis, and its method of administration is: three times on the one, and each 6-12 gram, warm water delivery service; Ante cibum, one after each meal all can.Just the clothes phase is 30 days, and dose can increase doubly, and after this dose is taken medicine continuously routinely, and three months is to observe with curative effect a course for the treatment of to judge.Chinese medicine mixture of the present invention is because of Chinese medicine preparation, reasonable recipe, have no side effect through clinical application toxicity test proof, therefore, but the patient takes Chinese patent medicine of the present invention the long period during treating, and need not dieting aspect the period in a medicine diet.
Four. curative effect determinate standard
Because psoriasis is the dermatosis of easily examining refractory, thereby psoriatic clinical treatment observation index and curative effect judgement mark
Standard is divided into: during the treatment, treatment finishes the back and visit long term in three periods.
1. treat phase clinical observation and curative effect judging standard
(1) clinical observation
1. squama: the propagation of epidermis cell is accelerated and hyperacanthosis, causes cuticular hyperkeratosis, makes epidermis renew the normal fast 7-8 of epidermis of rate doubly, namely per 3 days left and right sides desquamation one decks.Criterion after the medication is: squama reduces gradually or does not have new skin lesion and appears as effectively, otherwise is invalid.
2. substrate: it shows as substrate infiltration, plumpness, shows that the stratum germinativum increment of chrotoplast slows down, and hyperacanthosis fades, and the substrate skin lesion illustrate effectively, and the nothing change is soaked in substrate by thick attenuation, plump no attenuation, and it is invalid then to illustrate.
3. color: because the expansion of corium superficial part vascular plexus and blood capillary, its skin lesion has the non-fading red appearance of pressure more.After the medication, along with the alleviation of the state of an illness, the color of erythra is light red by red stain also, illustrates effectively, otherwise is invalid.
4. scope: skin lesion many and few indicate the light and heavy of the state of an illness.After the medication, new skin lesion stops to occur, and original erythra begins to dwindle from the edge, or therefrom the mind-set edge disappears gradually, and the erythra that part is big is divided into some fritters, illustrate effectively, on the contrary then invalid.
(2) curative effect judging standard:
1. produce effects: in above four, there are three to be clearly better, or four improvement that all have in various degree; Or binomial disappears binomial improvement in addition.
2. effective: as to have binomial to improve or a disappearance.
3. invalid: through one course for the treatment of of clinical application, skin lesion does not have and improves or increase the weight of.
2. treatment finishes back clinical observation and curative effect judging standard
(1) clinical observation:
1. whether squama: observing has new squama to occur.
2. substrate: whether erythra calms down, the smoothness of skin.
3. color: observe and have or not pigmentation or depigmentation.
4. whether scope: observing has new erythra to occur and the situation that disappears of former skin lesion.
(2) curative effect judging standard:
1. clinical cure: skin lesion all disappears, and only leaves pigmentation or takes off mistake.
2. produce effects: skin lesion disappears more than 70%.
3. effective: skin lesion disappears between the 30-70%.
4. invalid: skin lesion disappears below 30% or is not controlled on the contrary and increase the weight of.
3. visit clinical observation and curative effect judging standard long term
(1) clinical observation:
1. time: treatment finishes back more than 1 year or 2～three years, visits recovery from illness and recurrence situation.
2. case: visit case and cause of recurrence that observation post cures.
(2) curative effect judging standard:
1. recurrence: the skin lesion area is than enlarging before treating or increasing the weight of.
2. gently recurrence: the recurrence skin lesion is below 50% of former skin lesion.
Five. the clinical treatment result
Chinese medicine mixture of the present invention, through all kinds of psoriatics 300 examples of accepting for medical treatment altogether in 2,008 one 2012 4 years are carried out orally taken for curing, male's 146 examples wherein, women's 154 examples, the age is 14-60 year; Its clinical treatment result according to above-mentioned domestic unified criterion of therapeutical effect statistical computation is: recovery from illness (drug withdrawal observe more than 3 years not recidivist) 117 examples, and cure rate is 39%; Produce effects (drug withdrawal observe more than 1 year not recidivist) 102 examples, obvious effective rate is 34%; Effective (symptom obviously alleviates the scurf major part and comes off, and still has the small part silver bits person of not moving back) 60 examples, effective percentage is 20%; Invalid (take medicine 2 courses for the treatment of not alleviator) 21 examples, inefficiency 7%; Total effective rate is 93%, and not seeing has any toxic and side effects.
The specific embodiment
Embodiment 1
The described Chinese medicine mixture of present embodiment is to press the row weight portion to take by weighing each Chinese crude drug: 25 parts of Rhizoma Alismatis, 10 parts of Fructus Mumes, 15 parts of Radix Clematidis, 10 parts of Herba Schizonepetae, 15 parts of Flos Loniceraes, 15 parts of Rhizoma Coptidis, 10 parts in Poria, 15 parts of Herba Hedyotidis Diffusaes, 35 parts in Colla Corii Asini, 18 parts of Gypsum Fibrosum, 10 parts of Fructus Leonuris, 10 parts of the Fructus Kochiae, 20 parts in Semen Fagopyri Esculenti, 10 parts of Periostracum Serpentiss, 10 parts in the Radix Rehmanniae, 20 parts of Cortex Dictamnis, 20 parts of Semen Coicis, 25 parts of Ramulus Euonymis, 10 parts of Radix Sophorae Flavescentiss, 5 parts in Radix Glycyrrhizae, 35 parts of Exocarpium Benincasaes, 15 parts of Caulis Spatholobis, 15 parts of Fructus Chaenomeliss, 25 parts of Radix Polygoni Multifloris.
The described Chinese medicine mixture of present embodiment is that its preparation technology is: above-mentioned each medicinal raw material is made sublimed preparation according to the pharmaceutical methods that routine prepares sublimed preparation as the psoriatic endo-medicine for the treatment of.
Embodiment 2
Press the row weight portion and take by weighing each medical material: 20 parts of Rhizoma Alismatis, 40 parts of Fructus Mumes, 10 parts of Radix Clematidis, 40 parts of Herba Schizonepetae, 45 parts of Flos Loniceraes, 45 parts of Rhizoma Coptidis, 40 parts in Poria, 45 parts of Herba Hedyotidis Diffusaes, 45 parts in Colla Corii Asini, 15 parts of Gypsum Fibrosum, 40 parts of Fructus Leonuris, 40 parts of the Fructus Kochiae, 20 parts in Semen Fagopyri Esculenti, 40 parts of Periostracum Serpentiss, 40 parts in the Radix Rehmanniae, 60 parts of Cortex Dictamnis, 60 parts of Semen Coicis, 20 parts of Ramulus Euonymis, 40 parts of Radix Sophorae Flavescentiss, 20 parts in Radix Glycyrrhizae, 20 parts of Exocarpium Benincasaes, 20 parts of Caulis Spatholobis, 10 parts of Fructus Chaenomeliss, 30 parts of Radix Polygoni Multifloris.
The described Chinese medicine mixture of present embodiment is that its preparation technology is: above-mentioned each medicinal raw material is made packed powder according to the pharmaceutical methods that routine prepares powder as the psoriatic endo-medicine for the treatment of.
Embodiment 3
Press the row weight portion and take by weighing each medical material: 25 parts of Rhizoma Alismatis, 20 parts of Fructus Mumes, 20 parts of Radix Clematidis, 20 parts of Herba Schizonepetae, 25 parts of Flos Loniceraes, 25 parts of Rhizoma Coptidis, 20 parts in Poria, 25 parts of Herba Hedyotidis Diffusaes, 45 parts in Colla Corii Asini, 20 parts of Gypsum Fibrosum, 20 parts of Fructus Leonuris, 20 parts of the Fructus Kochiae, 25 parts in Semen Fagopyri Esculenti, 20 parts of Periostracum Serpentiss, 20 parts in the Radix Rehmanniae, 30 parts of Cortex Dictamnis, 30 parts of Semen Coicis, 25 parts of Ramulus Euonymis, 20 parts of Radix Sophorae Flavescentiss, 10 parts in Radix Glycyrrhizae, 35 parts of Exocarpium Benincasaes, 25 parts of Caulis Spatholobis, 15 parts of Fructus Chaenomeliss, 25 parts of Radix Polygoni Multifloris.
The described Chinese medicine mixture of present embodiment is that its preparation technology is: above-mentioned each medicinal raw material is made capsule according to the pharmaceutical methods that routine prepares capsule as the psoriatic endo-medicine for the treatment of.
Embodiment 4
Press the row weight portion and take by weighing each medical material: 30 parts of Rhizoma Alismatis, 30 parts of Fructus Mumes, 15 parts of Radix Clematidis, 30 parts of Herba Schizonepetae, 35 parts of Flos Loniceraes, 35 parts of Rhizoma Coptidis, 30 parts in Poria, 35 parts of Herba Hedyotidis Diffusaes, 35 parts in Colla Corii Asini, 25 parts of Gypsum Fibrosum, 30 parts of Fructus Leonuris, 30 parts of the Fructus Kochiae, 30 parts in Semen Fagopyri Esculenti, 30 parts of Periostracum Serpentiss, 30 parts in the Radix Rehmanniae, 50 parts of Cortex Dictamnis, 50 parts of Semen Coicis, 30 parts of Ramulus Euonymis, 30 parts of Radix Sophorae Flavescentiss, 15 parts in Radix Glycyrrhizae, 40 parts of Exocarpium Benincasaes, 15 parts of Caulis Spatholobis, 10 parts of Fructus Chaenomeliss, 30 parts of Radix Polygoni Multifloris.
The described Chinese medicine mixture of present embodiment is as the psoriatic endo-medicine for the treatment of, its preparation technology is: above-mentioned each medicinal raw material is made tablet according to the pharmaceutical methods that routine prepares tablet, (as conventional tablet, sugar coated tablet, film coated tablet etc.), and give conventional drug excipient (as starch, sucrose, lactose, calcium stearate, magnesium stearate etc.).
Embodiment 5
Press the row weight portion and take by weighing each medical material: 28 parts of Rhizoma Alismatis, 25 parts of Fructus Mumes, 20 parts of Radix Clematidis, 25 parts of Herba Schizonepetae, 30 parts of Flos Loniceraes, 30 parts of Rhizoma Coptidis, 25 parts in Poria, 30 parts of Herba Hedyotidis Diffusaes, 40 parts in Colla Corii Asini, 25 parts of Gypsum Fibrosum, 25 parts of Fructus Leonuris, 25 parts of the Fructus Kochiae, 25 parts in Semen Fagopyri Esculenti, 25 parts of Periostracum Serpentiss, 25 parts in the Radix Rehmanniae, 40 parts of Cortex Dictamnis, 40 parts of Semen Coicis, 25 parts of Ramulus Euonymis, 25 parts of Radix Sophorae Flavescentiss, 12 parts in Radix Glycyrrhizae, 35 parts of Exocarpium Benincasaes, 30 parts of Caulis Spatholobis, 15 parts of Fructus Chaenomeliss, 25 parts of Radix Polygoni Multifloris.
The described Chinese medicine mixture of present embodiment is that its preparation technology is as the psoriatic endo-medicine for the treatment of: above-mentioned each medicinal raw material is made pill according to the pharmaceutical methods that routine prepares pill, and give conventional drug excipient.
Embodiment 6
Press the row weight portion and take by weighing each medical material: 25 parts of Rhizoma Alismatis, 15 parts of Fructus Mumes, 15 parts of Radix Clematidis, 15 parts of Herba Schizonepetae, 30 parts of Flos Loniceraes, 30 parts of Rhizoma Coptidis, 15 parts in Poria, 30 parts of Herba Hedyotidis Diffusaes, 40 parts in Colla Corii Asini, 30 parts of Gypsum Fibrosum, 15 parts of Fructus Leonuris, 15 parts of the Fructus Kochiae, 35 parts in Semen Fagopyri Esculenti, 15 parts of Periostracum Serpentiss, 15 parts in the Radix Rehmanniae, 40 parts of Cortex Dictamnis, 40 parts of Semen Coicis, 15 parts of Ramulus Euonymis, 15 parts of Radix Sophorae Flavescentiss, 12 parts in Radix Glycyrrhizae, 40 parts of Exocarpium Benincasaes, 30 parts of Caulis Spatholobis, 10 parts of Fructus Chaenomeliss, 25 parts of Radix Polygoni Multifloris.
The described Chinese medicine mixture of present embodiment is that its preparation technology is: above-mentioned each medicinal raw material is made granule according to the pharmaceutical methods that routine prepares granule as the psoriatic endo-medicine for the treatment of.
Claims (4)
1. one kind is used for the treatment of psoriatic Chinese medicine mixture, it is characterized in that being made up of following medicaments in part by weight: Rhizoma Alismatis 10-40 part, Fructus Mume 10-40 part, Radix Clematidis 5-20 part, Herba Schizonepetae 10-40 part, Flos Lonicerae 15-45 part, Rhizoma Coptidis 15-45 part, Poria 10-40 part, Herba Hedyotidis Diffusae 15-45 part, Colla Corii Asini 15-50 part, Gypsum Fibrosum 10-30 part, Fructus Leonuri 10-40 part, Fructus Kochiae 10-40 part, Semen Fagopyri Esculenti 10-40 part, Periostracum Serpentis 10-40 part, Radix Rehmanniae 10-40 part, Cortex Dictamni 20-60 part, Semen Coicis 20-60 part, Ramulus Euonymi 5-30 part, Radix Sophorae Flavescentis 10-40 part, Radix Glycyrrhizae 5-20 part, Exocarpium Benincasae 15-50 part, Caulis Spatholobi 10-40 part, Fructus Chaenomelis 5-15 part, Radix Polygoni Multiflori 15-45 part.
2. according to claim 1ly be used for the treatment of psoriatic Chinese medicine mixture, it is characterized in that being formed by following medicaments in part by weight: Rhizoma Alismatis 20-30 part, Fructus Mume 20-30 part, Radix Clematidis 10-15 part, Herba Schizonepetae 20-30 part, Flos Lonicerae 25-35 part, Rhizoma Coptidis 25-35 part, Poria 20-30 part, Herba Hedyotidis Diffusae 25-35 part, Colla Corii Asini 20-45 part, Gypsum Fibrosum 15-25 part, Fructus Leonuri 20-30 part, Fructus Kochiae 20-30 part, Semen Fagopyri Esculenti 20-30 part, Periostracum Serpentis 20-30 part, Radix Rehmanniae 20-30 part, Cortex Dictamni 30-50 part, Semen Coicis 30-50 part, Ramulus Euonymi 10-20 part, Radix Sophorae Flavescentis 20-30 part, Radix Glycyrrhizae 10-15 part, Exocarpium Benincasae 20-40 part, Caulis Spatholobi 15-30 part, Fructus Chaenomelis 10-15 part, Radix Polygoni Multiflori 15-35 part.
3. according to claim 1ly be used for the treatment of psoriatic Chinese medicine mixture, it is characterized in that being formed by following medicaments in part by weight: 30 parts of Rhizoma Alismatis, 25 parts of Fructus Mumes, 15 parts of Radix Clematidis, 25 parts of Herba Schizonepetae, 30 parts of Flos Loniceraes, 30 parts of Rhizoma Coptidis, 25 parts in Poria, 30 parts of Herba Hedyotidis Diffusaes, 40 parts in Colla Corii Asini, 20 parts of Gypsum Fibrosum, 25 parts of Fructus Leonuris, 25 parts of the Fructus Kochiae, 25 parts in Semen Fagopyri Esculenti, 25 parts of Periostracum Serpentiss, 25 parts in the Radix Rehmanniae, 40 parts of Cortex Dictamnis, 40 parts of Semen Coicis, 15 parts of Ramulus Euonymis, 25 parts of Radix Sophorae Flavescentiss, 12 parts in Radix Glycyrrhizae, 30 parts of Exocarpium Benincasaes, 20 parts of Caulis Spatholobis, 10 parts of Fructus Chaenomeliss, 20 parts of Radix Polygoni Multifloris.
4. be used for the treatment of pill, sublimed preparation, powder, tablet, unguentum, decoction and the capsule that psoriatic Chinese medicine mixture is made according to the arbitrary claim of claim 1 to 3 is described.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101973371A CN103251850A (en) | 2013-05-24 | 2013-05-24 | Traditional Chinese medicine mixture for treating psoriasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101973371A CN103251850A (en) | 2013-05-24 | 2013-05-24 | Traditional Chinese medicine mixture for treating psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103251850A true CN103251850A (en) | 2013-08-21 |
Family
ID=48956283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013101973371A Withdrawn CN103251850A (en) | 2013-05-24 | 2013-05-24 | Traditional Chinese medicine mixture for treating psoriasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103251850A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1651038A (en) * | 2004-11-29 | 2005-08-10 | 李永泉 | Medicine for treating psoriasis |
| CN1879784A (en) * | 2006-05-15 | 2006-12-20 | 左建华 | A Chinese medicine for treating psoriasis |
| CN102228613A (en) * | 2011-05-31 | 2011-11-02 | 渠淑敏 | Chinese patent medicine for treating tinea capitis |
| CN102406866A (en) * | 2011-11-16 | 2012-04-11 | 王莲芬 | Chinese medicinal composition for treating psoriasis |
| CN102579975A (en) * | 2012-02-27 | 2012-07-18 | 王莲芬 | Traditional Chinese medicine mixture for treating psoriasis |
| CN102579895A (en) * | 2012-02-27 | 2012-07-18 | 王莲芬 | Traditional Chinese medicine composition for treating psoriasis |
-
2013
- 2013-05-24 CN CN2013101973371A patent/CN103251850A/en not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1651038A (en) * | 2004-11-29 | 2005-08-10 | 李永泉 | Medicine for treating psoriasis |
| CN1879784A (en) * | 2006-05-15 | 2006-12-20 | 左建华 | A Chinese medicine for treating psoriasis |
| CN102228613A (en) * | 2011-05-31 | 2011-11-02 | 渠淑敏 | Chinese patent medicine for treating tinea capitis |
| CN102406866A (en) * | 2011-11-16 | 2012-04-11 | 王莲芬 | Chinese medicinal composition for treating psoriasis |
| CN102579975A (en) * | 2012-02-27 | 2012-07-18 | 王莲芬 | Traditional Chinese medicine mixture for treating psoriasis |
| CN102579895A (en) * | 2012-02-27 | 2012-07-18 | 王莲芬 | Traditional Chinese medicine composition for treating psoriasis |
Non-Patent Citations (2)
| Title |
|---|
| 孔昭遐: "《孔昭遐验案选粹》", 29 February 2012, 上海科学技术出版社 * |
| 陈凯等: "《皮肤病中医特色治疗》", 31 January 2002, 辽宁科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102205107A (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN105056124A (en) | Medicine for treating hypertension and diabetes | |
| CN101041046A (en) | Chinese traditional medicine compound took orally for treating morning diarrhea | |
| CN1323711C (en) | Chinese medicine for treating liver cancer and carcinoma of pancreas | |
| CN102631512B (en) | Traditional Chinese medicine composition for curing chronic colitis | |
| CN103169883B (en) | Traditional Chinese medicine for treating infantile jaundice | |
| CN103211990A (en) | Chinese medicinal composition for treating oral ulcer | |
| CN103356932B (en) | A kind of pharmaceutical composition for the treatment of vulva squamous epithelial hyperplasia | |
| CN102579975B (en) | Traditional Chinese medicine mixture for treating psoriasis | |
| CN101897933A (en) | Chinese patent medicament for treating leucoderma | |
| CN104587186A (en) | Traditional Chinese medicinal composition for treating qi and blood deficiency | |
| CN100515462C (en) | Chinese medicine for treating cardiovascular and cerebrovascular trrombus and preparing method | |
| CN102579895B (en) | Traditional Chinese medicine composition for treating psoriasis | |
| CN103212041B (en) | Chinese medicinal composition treating coronary heart disease | |
| CN102641368A (en) | Traditional Chinese medicine for treating beriberi | |
| CN103536842A (en) | Mixture for treating psoriasis | |
| CN104117018A (en) | Traditional Chinese medicine composition for treating coronary heart disease | |
| CN103381246B (en) | Traditional Chinese medicine for treating psoriasis | |
| CN102552824B (en) | Traditional Chinese medicine prepared prescription for treating psoriasis | |
| CN103251850A (en) | Traditional Chinese medicine mixture for treating psoriasis | |
| CN102416099A (en) | Traditional Chinese medicine for treating psoriasis | |
| CN105617162A (en) | Traditional Chinese medicine composition for treating aphthae | |
| CN112263663A (en) | Traditional Chinese medicine composition for treating gynecological diseases related to yang deficiency constitution | |
| CN103083552B (en) | Pills for treating neurodermatitis | |
| CN103381247B (en) | Traditional Chinese medicinal composition for treating psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C04 | Withdrawal of patent application after publication (patent law 2001) | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20130821 |